Sanofi (NASDAQ:SNY – Get Rating) had its price objective lifted by stock analysts at JPMorgan Chase & Co. from €105.00 ($108.25) to €115.00 ($118.56) in a research report issued to clients and investors on Monday, The Fly reports.
A number of other analysts have also weighed in on SNY. Morgan Stanley increased their target price on shares of Sanofi from €110.00 ($113.40) to €112.00 ($115.46) in a report on Friday, April 22nd. UBS Group increased their price target on shares of Sanofi from €118.00 ($121.65) to €119.00 ($122.68) and gave the stock a “buy” rating in a research note on Tuesday, June 7th. Credit Suisse Group increased their price target on shares of Sanofi from €105.00 ($108.25) to €110.00 ($113.40) and gave the stock an “outperform” rating in a research note on Friday, July 22nd. Barclays increased their price target on shares of Sanofi from €90.00 ($92.78) to €105.00 ($108.25) in a research note on Thursday, April 14th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of Sanofi from €85.00 ($87.63) to €90.00 ($92.78) and gave the stock a “sell” rating in a research note on Friday, July 29th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $111.14.
Sanofi Stock Performance
Sanofi stock opened at $48.80 on Monday. The company has a current ratio of 1.29, a quick ratio of 0.34 and a debt-to-equity ratio of 0.22. The firm has a 50-day moving average of $51.17 and a 200-day moving average of $52.14. The firm has a market cap of $123.51 billion, a P/E ratio of 16.21, a P/E/G ratio of 1.23 and a beta of 0.48. Sanofi has a 1-year low of $46.92 and a 1-year high of $58.10.
Hedge Funds Weigh In On Sanofi
About Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Featured Articles
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Pinterest Shares Are Soaring After Earnings, Is The Stock A Buy?
- Market Fundamentals Drive Results For The Williams Companies
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.